user avatar
d.planchard
@dplanchard
Thoracic Oncologist - Prof at University Paris Saclay - Head of Thoracic Group, Medical Oncology Dpt- Gustave Roussy - Villejuif - France ๐Ÿ‡ซ๐Ÿ‡ท and INSERM U981
Joined July 2009
216
Following
6,675
Followers
Posts
  • user avatar
    d.planchard
    @dplanchard
    Nov 9, 2023
    Proud to lead this publication with P.A.Janne and all the co-authors...thank you to the patients who actively participated in this research and enabled us to offer a new therapeutic option for our EGFRmut patients in 1st-line. @NEJM @DanaFarberNews @GustaveRoussy @CICThoraciques
    19K
  • user avatar
    d.planchard
    @dplanchard
    Feb 9, 2019
    Metastatic NSCLC ESMO Guidelines including some corrections @Annals_Oncology @myESMO @peters_solange
  • user avatar
    d.planchard
    @dplanchard
    Sep 9, 2022
    A pleasure to go to #ESMO2022 for this 1st day...don't hesitate to take metro line 6 for this view! @myESMO #Paris
  • user avatar
    d.planchard
    @dplanchard
    Jul 20, 2022
    Always impressed by the rapidity of tumor regression after only 1 injection of Datopotamab deruxtecan (ADC-anti Trop2) (ICARUS-Lung01trial @GustaveRoussy ). NSCLC with an EGFRmut (Del19) after Osimertinib then Platinum-Pemetrexed-Pembrolizumabโ€ฆ @CICThoraciques
  • user avatar
    d.planchard
    @dplanchard
    Jan 17, 2023
    What a great update of the 2023 metastatic non-oncogene addicted NSCLC @myESMO guideline. A pleasure to participate under the coordination of @HendriksLizza and @MartinReck2 and with all experts @APassaroMD @peters_solange @TonyMok9 @bensolomon1 @JessicaMenis @SmitEgbert โ€ฆ
    13K
  • user avatar
    d.planchard
    @dplanchard
    May 30, 2020
    Type of major tumor response that can be observed with Trastuzumab Deruxtecan in pts with HER2 mutated NSCLC...@GustaveRoussy #ASCO2020
  • user avatar
    d.planchard
    @dplanchard
    Nov 24, 2018
    Nice IO overview by @peters_solange @myESMO #ESMOAsia18
  • user avatar
    d.planchard
    @dplanchard
    Aug 22, 2020
    Nice summury of IO first line nsclc by @peters_solange @myESMO #esmoacademy20
  • user avatar
    d.planchard
    @dplanchard
    Oct 21, 2023
    Impressive to see @StephenVLiu at work tweeting in real time : A professional ๐Ÿ˜ ! @myESMO #ESMO23
    5.1K
  • user avatar
    d.planchard
    @dplanchard
    Oct 9, 2023
    I'm very proud of my appointment to this wonderful institution and faculty, and I'd like to thank the directors for their unfailing support! @GustaveRoussy @MedecineUPSay @GroupeUnicancer @barlesi
    user avatar
    Gustave Roussy
    @GustaveRoussy
    Oct 9, 2023
    David Planchard, oncologue thoracique ร  @GustaveRoussy, est nommรฉ Professeur associรฉ auprรจs de l'@UnivParisSaclay par le Ministรจre de l'Enseignement Supรฉrieur et de la Recherche (@sup_recherche). Un grand bravo pour cette belle nomination ! ๐Ÿ‘ ๐Ÿ”— gustaveroussy.fr/fr/david-plancโ€ฆ
    10K
  • user avatar
    d.planchard
    @dplanchard
    Nov 23, 2019
    IMbrave150, unresctable HCC, impressive results and new standard of care....#ESMOAsia19 @myESMO
  • user avatar
    d.planchard
    @dplanchard
    Oct 6, 2018
    Impressive evolution of therapeutic options in squamous NSCLC with IO @Annals_Oncology @myESMO @peters_solange
  • user avatar
    d.planchard
    @dplanchard
    Apr 11, 2022
    Neo vs Adjuvant Chemo IOโ€ฆ? Need more strategy studies in resected NSCLCโ€ฆ #AACR2022 @nicogirardcurie
  • user avatar
    d.planchard
    @dplanchard
    Sep 8, 2021
    Dabrafenib+Trametinib confirms its place as standard therapy (1st or 2nd line, ORR: 63.9/68.4% and mPFS: 10.8/10.2 mo and mOS: 17.3/18.2 mo with 5-years rates 22/19%) in our BRAFV600E NSCLC pts. Update at 5yearsโ€ฆ@JTOonline #BRAF @IASLC